Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 olaparib maintenance after first-line platinum in BRCA-mutated advanced ovarian cancer
jRCT2080222311Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Olaparib maintenance with Placebo (2 arms). Started Nov 2013; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2080222311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222311.